Liangliang Cai

Dr. Liangliang Cai


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 November 2020 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
LCLiangliang Cai
Liangliang Cai
JDJianchun Duan
Jianchun Duan
LQLi Qian
Li Qian
ZWZhijie Wang
Zhijie Wang
SWShuhang Wang
Shuhang Wang
JWjie wang
jie wang
The drug resistance of first-line crizotinib therapy for ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) fusion non-small cell lung cancer (NSCLC) is inevitable. Whether the administration of immune checkpoint inhibitor (ICI) therapy is suitable for ROS 1 fusion NSCLCs or after the development of crizotinib resistance is still unknown. In this study, five different crizotinib resistant concentration cell lines (HCC78CR1-5) from primary sensitive HCC78 cells were cultured. Ba/F3 cells expressing crizotinib sensitive ROS1 fusion and crizotinib resistant ROS1-G2032R mutation were used to explore the relationship between ROS1 fusion, ROS1-G2032R mutation and programmed death-ligand 1 (PD-L1) expression and the clinical potential of anti-PD-L1 ICI therapy. The signaling pathway net was compared between HCC78 and HCC78CR1-5 cells using RNA sequencing. Anti- PD-L1 ICI therapy was performed on mouse xenograft models with Ba/F3 ROS1 fusion or ROS1-G2032R mutation. HCC78CR1-5 showed more immunogenicity than HCC78 in immune-related pathways. The PD-L1 expression level was remarkably higher in HCC78CR1-5 with ROS1 fusion upregulation than HCC78 primary cell. Furthermore, the expression of PD-L1 was down-regulated by RNA interference with ROS1 siRNAs and up-regulated lower in Ba/F3 ROS1-G2032R resistant mutation than ROS1 fusion. Western blotting analysis showed the ROS1–SHP2 signaling pathway activation in HCC78CR1-5 cells, Ba/F3 ROS1 fusion and ROS1-G2032R resistant mutation. Mouse xenograft models with Ba/F3 ROS1 fusion showed more CD3+PD-1+ T cells both in blood and tissue, and more sensitivity than the cells with Ba/F3 ROS1-G2032R resistant mutation after anti-PD-L1 therapy. Our findings indicate that PD-L1 upregulation depends on ROS1 fusion more than ROS1-G2032R mutation. We share our insights of NSCLCs treatment management into the use of anti-PD-L1 ICI therapy in ROS1 fusion and not in ROS1-G2032R resistant mutation.

1 February 2022 in Journal of Zhejiang University (Medical Sciences)
Verified
Journal Article
Closed access
QCQiu Chen
Qiu Chen
LCLiangliang Cai
Liangliang Cai
JLJingyan Liang
Jingyan Liang
目的:分析膀胱癌相关基因特点,建立膀胱癌临床预后模型。方法:运用GO分析、加权基因共表达网络(WGCNA)、单因素Cox回归、LASSO回归分析和多因素Cox回归,回顾性研究癌症基因组图谱数据库(TCGA)、基因型组织表达数据库(GTEx)中膀胱癌与正常膀胱组织的RNA-seq数据,建立临床预后模型,并结合Kaplan-Meier生存图、ROC曲线图验证临床预后模型的准确性。结果:分析得到膀胱癌相关差异表达基因(DEG)共2308个。WGCNA拟合六个基因模块,发现最关键的临床表征“总体生存状态(OSS)”。运用单因素Cox回归与LASSO回归分析筛选出24个临床预后相关基因,进一步多因素Cox回归确立由9个基因组成的膀胱癌临床预后模型。通过Kaplan-Meier生存分析得到训练集(n =203)和测试集(n =203)两组病人总体生存状态:训练(测试)集里低风险组、高风险组三年生存率分别是59.8%(68.9%)、31.8%(32.7%)。训练集与测试集中绘制的ROC曲线,其曲线下面积(AUC)均在0.7以上。结论:本研究基于TCGA与GTEx数据库构建膀胱癌临床预后模型,具有潜在的预后与临床辅助诊断价值。

23 November 2022 in Journal of Oncology
Verified
Journal Article
Open access
PDF file
TLTingting Liu
Tingting Liu
LCLiangliang Cai
Liangliang Cai
HHHujia Hua
Hujia Hua
XJXingyu Jiang
Xingyu Jiang
XXXintian Xu
Xintian Xu
JDJian Chun Duan
Jian Chun Duan
Background. The association involving cuprotosis, molecular subtype, and specific immune cell groups in the tumor microenvironment has been focused on by more recent studies. In lung adenocarcinoma (LUAD), the potential functions of cuprotosis remain elusive. Methods. The cuprotosis regulations and tumor immune profile of 567 LUAD patients and the correlation between the cuprotosis patterns and the immune landscape were comprehensively evaluated. The cuprotosisScore was calculated using principal component analysis (PCA). The prognostic significance of the cuprotosisScore was evaluated by Cox regression statistics analysis. Results. Five cuprotosisClusters (named mc1, 2, 3, 4, 5)characterized by differences in expression of immunomodulatory genes, mRNA, or lncRNA expression, and prognosis were identified. We established cuprotosisScore to quantify the cuprotosis pattern of individual LUAD patients. As is shown in further analyses, the cuprotosisScore was a relatively potential independent prognostic factor of LUAD involved in mc1. Finally, the prognostic value of the cuprotosisScore and its association with tumor immune microenvironment (iTME) of LUAD in five cuprotosisClusters were verified. Conclusions. We demonstrated the correlation between cuprotosis modification, the molecular subtype, and tumor immune landscape in LUAD. The cuprotosisCluster with high cuprotosisScore and high tumor mutation burden (TMB) was identified with a good prognosis and immune functions. The comprehensive evaluation of cuprotosis patterns in individual LUAD patients enhances the understanding of iTME and gives a new insight toward improved immune treatment strategies for LUAD patients.

6 June 2023 in BMC Cancer
Verified
Journal Article
Open access
PDF file
LCLiangliang Cai
Liangliang Cai
HHHujia Hua
Hujia Hua
XJXingyu Jiang
Xingyu Jiang
XXXintian Xu
Xintian Xu
HBHua Bai
Hua Bai
JDJianchun Duan
Jianchun Duan
The association involving mismatch repair (MMR) genes, molecular subtype and specific immune cell group in tumor microenvironment has been focused by more recent studies. Its prognosis value in lung adenocarcinoma (LUAD) neoadjuvant chemotherapy remains elusive. The correlation between the MMR gene patterns and the immune landscape were comprehensively evaluated. The MMRScore was calculated using principal component analysis (PCA) after grouping using R/mclust package. The prognostic significance of the MMRScore was evaluated by Kaplan-merrier analysis. Then a cohort of 103 Chinese LUAD patients was collected for neoadjuvant chemotherapy prognosis evaluation and validation using MMRScore. Four MMRclusters (mc1, 2, 3, 4)-characterized by differences in extent of aneuploidy, expression of immunomodulatory (IM) genes, mRNA expression, lncRNA expression and prognosis were identified. We established MMRscore to quantify the MMR pattern of individual LUAD patients. As is shown in further analyses, the MMRscore was a potential independent prognostic factor of LUAD. Finally, the prognostic value of the MMRscore and its association with tumor immune microenvironment (TIME) of LUAD were verified in Chinese LUAD cohort. We demonstrated the correlation between MMR gene pattern, the CNV and tumor immune landscape in LUAD. A MMRcluster mc2 with high MMRscore, high TMB and high CNV subtype was identified with poor prognosis and infiltrating immunocyte. The comprehensive evaluation of MMR patterns in individual LUAD patients enhances the understanding of TIME and gives a new insight toward improved immune treatment strategies for LUAD patients compared to neoadjuvant chemotherapy.

Verified
Journal Article
Open access
PDF file
NZNuoyan Zhu
Nuoyan Zhu
LCLiangliang Cai
Liangliang Cai
LQLi Qian
Li Qian
The study of gene anomalies linked to thyroid cancer is gaining more and more attention, and these molecular indicators can offer scholarly support for thyroid cancer diagnosis, therapy selection, and prognosis. Genotype–tissue expression pan-cancer data and The Cancer Genome Atlas (TCGA) were used to investigate the expression of GZMK, TREM2, and OR4D10. In order to assess the relationship between GZMK, TREM2, and OR4D10 expression and patient outcome, TCGA clinical survival data were used. We used the clusterProfiler R software tool to conduct enrichment analysis of GZMK, TREM2, and OR4D10. Moreover, TCGA database analysis was used to assess the relationship between immune cell infiltration and GZMK, TREM2, and OR4D10 expression. GZMK, TREM2, and OR4D10 were strongly expressed in several kinds of malignancies including thyroid cancer. Gene sets related to proliferation that are involved in leukocyte cell–cell adhesion and mononuclear cell differentiation were significantly correlated with high expression of GZMK, TREM2, and OR4D10. Additional investigation revealed a correlation between high T cell and DC (dendritic cell) infiltration scores and high expression of GZMK, TREM2, and OR4D10. According to our research, OR4D10, TREM2, and GZMK could all be genes associated with thyroid cancer.

19 December 2025 in Biology
Verified
Journal Article
Open access
PDF file
NZNuoyan Zhu
Nuoyan Zhu
JWJiahui Wang
Jiahui Wang
LCLiangliang Cai
Liangliang Cai
Immune checkpoint blockade is one of the current treatments for glioblastoma (GBM), which is still a very aggressive and treatment-resistant tumor of the central nervous system. This study focused on the LYZ gene to find new therapeutic targets. We performed a thorough screening of differential gene expressions between GBM and normal samples using many databases (TCGA, GTEx, GEO, and CGGA). Because LYZ is significantly upregulated in GBM tissues and is associated with shorter patient survival periods, we identified it as a gene of interest. LYZ’s position on the exterior side of the plasma membrane and its participation in leukocyte-mediated immunity were identified by functional enrichment analysis, indicating a role in cell surface immune responses. Significant associations between LYZ expression and particular immune cell types were found using immune infiltration analysis, suggesting that LYZ may have an impact on the tumor microenvironment. Within GBM, single-cell research verified LYZ expression in macrophages and monocytes. LYZ was shown to express differently in GBM cell lines than in normal glial cells, according to cellular experimental verification. The LYZ gene’s functional importance in the pathophysiology of GBM was highlighted by the dramatic reduction in cell proliferation, motility, and invasion that resulted from its knockout. These results suggest that LYZ is a viable therapeutic target and possible GBM diagnostic biomarker, which calls for more research into its mechanisms of action and potential clinical use.